中国P站

Dendritic Cells; Respiratory Viruses; Antiviral Immunity; Mucosal Immunity; Vaccines; Airway Epithelium; T Cells; Immunopathology; Co-infections; Adjuvants

Introduction

Mucosal Dendritic Cells (DCs) are critical for initiating antiviral immunity in the respiratory tract [1].

They capture antigens, migrate to lymph nodes, and activate T cells, which shapes the adaptive immune response against respiratory viruses [1].

The heterogeneity of DC subsets in the respiratory mucosa contributes to diverse antiviral responses [2].

Different DC subsets exhibit varying antigen-presenting capabilities and cytokine profiles, influencing the balance between immunity and tolerance [2].

Respiratory viruses can exploit DC functions to evade immune responses [3].

Some viruses interfere with DC maturation, antigen presentation, or cytokine production, which leads to impaired antiviral immunity [3].

The location of DCs within the respiratory mucosa affects their interaction with viruses and subsequent immune responses [4].

DCs in different locations might encounter different viral strains or respond differently to infection [4].

DC-based vaccines can enhance antiviral immunity in the respiratory tract [5].

These vaccines can be designed to deliver specific viral antigens to DCs, promoting strong T cell responses and long-term protection [5].

The role of mucosal DCs in regulating immune responses to influenza virus is intricate; DCs contribute to both protective immunity and immunopathology [6].

Understanding these mechanisms is essential for developing effective influenza vaccines and therapies [6].

Studies highlight the importance of specific DC subsets, such as CD103+ DCs, in cross-presenting viral antigens and initiating CD8+ T cell responses in the lungs [7].

These cells are crucial for controlling viral infections [7].

Research suggests that targeting DCs with specific adjuvants can enhance vaccine efficacy against respiratory viruses [8].

Adjuvants can activate DCs and promote the development of robust and long-lasting immune responses [8].

The interaction between DCs and the Airway Epithelium is critical for shaping antiviral immunity [9].

Epithelial cells can release cytokines that activate DCs, leading to the recruitment of immune cells to the site of infection [9].

Emerging research focuses on the role of DCs in the context of co-infections with multiple respiratory viruses [10].

The presence of one virus can alter DC responses to subsequent infections, affecting the overall outcome of disease [10].

Description

Dendritic Cells (DCs) play a pivotal role in initiating antiviral immunity within the respiratory system [1]. They function as sentinels, capturing antigens, migrating to lymph nodes, and activating T cells, which are crucial for adaptive immune responses against respiratory viruses [1]. The complexity of DC subsets in the respiratory mucosa leads to various antiviral reactions [2]. These subsets exhibit distinct antigen-presenting capabilities and cytokine profiles, which influence the delicate balance between immunity and tolerance [2].

However, respiratory viruses are known to exploit DC functions to evade immune responses [3]. Certain viruses can interfere with DC maturation, antigen presentation, or cytokine production, leading to diminished antiviral immunity [3]. The location of DCs within the respiratory mucosa plays a significant role in how they interact with viruses and the subsequent immune responses [4]. DCs in different locations may encounter diverse viral strains or display varied responses to infection [4].

DC-based vaccines show promise in enhancing antiviral immunity in the respiratory tract [5]. These vaccines can be engineered to deliver specific viral antigens to DCs, thereby promoting robust T cell responses and long-term protection [5]. The role of mucosal DCs in regulating immune responses to the influenza virus is multifaceted; they contribute to both protective immunity and the development of immunopathology [6]. A thorough understanding of these mechanisms is crucial for creating effective influenza vaccines and therapies [6].

Studies emphasize the importance of specific DC subsets, such as CD103+ DCs, in cross-presenting viral antigens and initiating CD8+ T cell responses within the lungs [7]. These cells are critical for controlling viral infections [7]. Research indicates that targeting DCs with specific adjuvants can enhance vaccine efficacy against respiratory viruses [8]. Adjuvants can activate DCs and foster the development of robust and long-lasting immune responses [8]. The interaction between DCs and the Airway Epithelium is essential for shaping antiviral immunity [9]. Epithelial cells can release cytokines that activate DCs, which leads to the recruitment of immune cells to the site of infection [9]. Emerging research is focusing on the role of DCs in the context of co-infections with multiple respiratory viruses [10]. The presence of one virus can alter DC responses to subsequent infections, impacting the overall outcome of disease [10].

Conclusion

Mucosal Dendritic Cells (DCs) are vital for initiating antiviral immunity in the respiratory tract. They sample antigens, migrate to lymph nodes, and activate T cells, shaping the adaptive immune response against respiratory viruses. The heterogeneity of DC subsets in the respiratory mucosa contributes to diverse antiviral responses, with different DC subsets exhibiting distinct antigen-presenting capabilities and cytokine profiles, influencing the balance between immunity and tolerance. Respiratory viruses can exploit DC functions to evade immune responses by interfering with DC maturation, antigen presentation, or cytokine production, leading to impaired antiviral immunity. The location of DCs within the respiratory mucosa influences their interaction with viruses and subsequent immune responses. DC-based vaccines can enhance antiviral immunity by delivering specific viral antigens to DCs, promoting robust T cell responses and long-term protection. The role of mucosal DCs in regulating immune responses to influenza virus is complex, with DCs contributing to both protective immunity and immunopathology. Targeting DCs with specific adjuvants can enhance vaccine efficacy, and the interaction between DCs and the Airway Epithelium is critical for shaping antiviral immunity. Emerging research focuses on the role of DCs in the context of co-infections with multiple respiratory viruses.

References

1. Anu V, Sushree M, Katherine NG (2023) .J Exp Med 220:e20221457.

   , ,

2. Matthew C, Niall M, Muzlifah H (2022) .Immunology 165:9-22.

   , ,

3. Matthew RE, Nicholas JM, Katelyn MW (2021) .PLoS One 16:e0251313.

   , ,

4. Yang L, Yonghoon K, Andreas L (2020) .Mucosal Immunol 13:559-571.

   , ,

5. Mi-Sun L, Min S, Young-Kyu K (2019) .Vaccine 37:7124-7132.

   , ,

6. Hyun-Phil M, Min K, Hyun-Jeong K (2024) .J Immunol 212:702-712.

   , ,

7. Claudia EvdS, Johan HK, Marieke MG (2023) .PLoS Pathog 19:e1011504.

   , ,

8. Lei W, Xiao H, Ying G (2022) .J Control Release 349:714-726.

   , ,

9. Filipa MS, Diogo F, Ana A (2021) .Front Immunol 12:623032.

   , ,

10. Seung-Yun C, Yunmi J, Ji-Hye L (2020) .PLoS One 15:e0236559.

    , ,